More than 10 percent of America’s coal miners with 25 or more years of experience have black lung disease, the highest rate recorded in roughly two decades, according to a government study released on Thursday that showed cases concentrated heavily in central Appalachia.
(Reuters Health) - Gender disparities in medical careers - in position, pay and publishing - start early, but even small systemic changes in training programs could begin to narrow these gaps, says a group of Harvard Medical School doctors.
The Trump administration has proposed a rule that would scale back protections currently in place that allow rebates between drug manufacturers and insurers and pharmacy benefits managers, according to the Office of Management and Budget (OMB) website.
Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading cause of vision loss among people over 65, met the main goal in two late-stage studies.
Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.
The Chinese bulk manufacturer of the common blood and heart drug valsartan said it was recalling the product from consumers in the United States and would halt supplies to the country, after an impurity linked to cancer had been detected.
Roche's hopes of clinching more of the lung cancer treatment market with its Tecentriq immunotherapy had a major setback on Thursday, when a trial failed to deliver survival data the Swiss drugmaker needs to challenge rival Merck.
Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.
Federal prosecutors on Wednesday charged a pharmacy technician who worked at a hospital with making false statements during an investigation related to a Massachusetts compounding pharmacy at the center of a deadly fungal meningitis outbreak in 2012.
AngioDynamics Inc has agreed to pay the U.S. government $12.5 million to resolve allegations it caused healthcare providers to submit false claims to federal healthcare programs over the use of two medical devices, the Justice Department said on Wednesday.